CN106535900A - 使用braf抑制剂的伤口愈合 - Google Patents
使用braf抑制剂的伤口愈合 Download PDFInfo
- Publication number
- CN106535900A CN106535900A CN201580036956.XA CN201580036956A CN106535900A CN 106535900 A CN106535900 A CN 106535900A CN 201580036956 A CN201580036956 A CN 201580036956A CN 106535900 A CN106535900 A CN 106535900A
- Authority
- CN
- China
- Prior art keywords
- dressings
- braf inhibitor
- pharmaceutical composition
- braf
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989398P | 2014-05-06 | 2014-05-06 | |
| US61/989,398 | 2014-05-06 | ||
| PCT/US2015/029562 WO2015171833A1 (en) | 2014-05-06 | 2015-05-06 | Wound healing using braf inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106535900A true CN106535900A (zh) | 2017-03-22 |
Family
ID=54392978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580036956.XA Pending CN106535900A (zh) | 2014-05-06 | 2015-05-06 | 使用braf抑制剂的伤口愈合 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170100345A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3139927A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017514866A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106535900A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015171833A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111417730A (zh) * | 2017-11-20 | 2020-07-14 | 托雷莫治疗股份公司 | 诊断方法 |
| CN113382717A (zh) * | 2019-02-12 | 2021-09-10 | 鲁特里斯制药有限公司 | 局部braf抑制剂组合物用于治疗放射性皮炎的用途 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069511A (zh) | 2016-03-10 | 2018-12-21 | 鲁特里斯制药有限公司 | Braf抑制剂用于治疗皮肤反应的用途 |
| CA3028429A1 (en) * | 2016-06-21 | 2017-12-28 | The Regents Of The University Of California | Wound healing using braf inhibitors |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11998550B2 (en) | 2017-04-20 | 2024-06-04 | Thomas Jefferson University | Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation |
| SI3661515T1 (sl) * | 2017-07-29 | 2022-06-30 | Lutris Pharma Ltd. | Novi BRaf inhibitorji in njihova uporaba za zadravljenje kožnih reakcij |
| US11458139B2 (en) * | 2017-08-08 | 2022-10-04 | Memorial Sloan Kettering Cancer Center | Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| DE102019129444A1 (de) * | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050214325A1 (en) * | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| WO2005091891A2 (en) * | 2004-03-11 | 2005-10-06 | Kythera Biopharmaceuticals, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| US20110118245A1 (en) * | 2008-03-17 | 2011-05-19 | Sunny Abraham | Raf kinase modulator compounds and methods of use thereof |
| WO2011090738A2 (en) * | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| US20120010229A1 (en) * | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
| US20130231347A1 (en) * | 2010-11-19 | 2013-09-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment with braf inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977428A (en) * | 1996-12-20 | 1999-11-02 | Procyte Corporation | Absorbent hydrogel particles and use thereof in wound dressings |
| JP4263402B2 (ja) * | 2001-12-27 | 2009-05-13 | 三笠製薬株式会社 | 創傷治療用製剤 |
| DK1478358T3 (da) * | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| MY153898A (en) * | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| DE102005060461A1 (de) * | 2005-12-17 | 2007-07-12 | Paul Hartmann Ag | Medizinische Zusammensetzung |
| US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
| EP2419103A1 (en) * | 2009-04-15 | 2012-02-22 | Fondazione IRCCS Istituto Nazionale dei Tumori | Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability |
| US9290507B2 (en) * | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| CN103153290B (zh) * | 2010-10-11 | 2018-01-16 | 普渡研究基金会 | 有助于伤口愈合的抗微生物制剂 |
| AU2012253525B2 (en) * | 2011-05-10 | 2016-09-22 | Brunangelo Falini | Hairy cell leukemia biomarkers and methods of using same |
| US20140093498A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| CN103520162B (zh) * | 2013-10-15 | 2015-11-18 | 中国科学院上海药物研究所 | 达拉菲尼抑制程序性坏死和保护肝脏的应用 |
-
2015
- 2015-05-06 CN CN201580036956.XA patent/CN106535900A/zh active Pending
- 2015-05-06 US US15/309,190 patent/US20170100345A1/en not_active Abandoned
- 2015-05-06 JP JP2016566754A patent/JP2017514866A/ja active Pending
- 2015-05-06 WO PCT/US2015/029562 patent/WO2015171833A1/en not_active Ceased
- 2015-05-06 EP EP15789274.6A patent/EP3139927A4/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005091891A2 (en) * | 2004-03-11 | 2005-10-06 | Kythera Biopharmaceuticals, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| US20050214325A1 (en) * | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| US20110118245A1 (en) * | 2008-03-17 | 2011-05-19 | Sunny Abraham | Raf kinase modulator compounds and methods of use thereof |
| WO2011090738A2 (en) * | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| US20120010229A1 (en) * | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
| US20130231347A1 (en) * | 2010-11-19 | 2013-09-05 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment with braf inhibitor |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111417730A (zh) * | 2017-11-20 | 2020-07-14 | 托雷莫治疗股份公司 | 诊断方法 |
| CN113382717A (zh) * | 2019-02-12 | 2021-09-10 | 鲁特里斯制药有限公司 | 局部braf抑制剂组合物用于治疗放射性皮炎的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3139927A4 (en) | 2017-12-13 |
| WO2015171833A1 (en) | 2015-11-12 |
| EP3139927A1 (en) | 2017-03-15 |
| JP2017514866A (ja) | 2017-06-08 |
| US20170100345A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170100345A1 (en) | Wound healing using braf inhibitors | |
| TWI812581B (zh) | 激酶調節及其適應症 | |
| ES2863996T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| JP6755895B2 (ja) | 皮膚の病的状態を治療するための組成物及び方法 | |
| CN102711686A (zh) | 含有低甲基化试剂以及组蛋白脱乙酰基酶抑制剂的药物组合物 | |
| KR20180037228A (ko) | 항박테리아 치료제 및 예방제 | |
| US20250367229A1 (en) | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | |
| JP2024503892A (ja) | ピロロピリジン-アニリン化合物の結晶形 | |
| US20190262343A1 (en) | Wound healing using braf inhibitors | |
| TWI826738B (zh) | 癌症治療方法 | |
| EP2211849B1 (en) | Dexanabinol with inhibitors of BRAF or MEK for the treatment of melanoma. | |
| WO2025157286A1 (zh) | 包含prmt5抑制剂和mat2a抑制剂的药物组合物 | |
| BRPI0620242A2 (pt) | combinação compreendendo a combretastatina e agentes anti-cancerìgenos | |
| WO2025157284A1 (zh) | 包含prmt5抑制剂和化疗剂的药物组合物 | |
| WO2025157288A1 (zh) | 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物 | |
| CN115697317A (zh) | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 | |
| US12582649B2 (en) | Compositions and methods for hair follicle regeneration | |
| AU2023360058A1 (en) | Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones. | |
| WO2014184726A2 (en) | Compounds and their use in therapy | |
| CN105311636B (zh) | 一种抗疱疹病毒软膏剂及其制备方法 | |
| EP4720079A1 (en) | Mitochondria specific transcription inhibitors | |
| CN118786125A (zh) | 氮杂环丁烷衍生物的用途及治疗方法 | |
| HK40086626A (en) | Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia | |
| EP3010513B1 (en) | Combination of ro5503781 and capecitabine for cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |